Unknown

Dataset Information

0

Admission blood glucose level and outcome in patients requiring venoarterial extracorporeal membrane oxygenation.


ABSTRACT:

Background

Patients with cardiogenic shock or cardiac arrest undergoing venoarterial extracorporeal membrane oxygenation (V-A ECMO) frequently present with blood glucose levels out of normal range. The clinical relevance of such findings in the context of V-A ECMO is unknown. We therefore investigated the prognostic relevance of blood glucose at time of cannulation for V-A ECMO.

Methods

We conducted a single-center retrospective registry study. All patients receiving V-A ECMO from October 2010 to January 2020 were included if blood glucose level at time of cannulation were documented. Patients were divided in five groups according to the initial blood glucose level ranging from hypoglycemic (< 80 mg/dl), normoglycemic (80-140 mg/dl), to mild (141-240 mg/dl), moderate (241-400 mg/dl), and severe (> 400 mg/dl) hyperglycemia, respectively. Clinical presentation, arterial blood gas analysis, and survival were compared between the groups.

Results

392 patients met inclusion criteria. Median age was 62 years (51.5-70.0), SAPS II at admission was 54 (43.5-63.0), and 108/392 (27.6%) were female. 131/392 were discharged alive (hospital survival 33.4%). At time of cannulation, survivors had higher pH, hemoglobin, calcium, bicarbonate but lower potassium and lactate levels compared to non-survivors (all p < 0.01). Outcome of patients diagnosed with particularly high (> 400 mg/dl) and low (< 80 mg/dl) blood glucose at time of V-A ECMO cannulation, respectively, was worse compared to patients with normoglycemic, mildly or moderately elevated values (p = 0.02). Glucose was independently associated with poor outcome after adjustment for other predictors of survival and persisted in all investigated subgroups.

Conclusion

Arterial blood glucose at time of V-A ECMO cannulation predicts in-hospital survival of patients with cardiac shock or after ECPR. Whether dysglycemia represents a potential therapeutic target requires further evaluation in prospective studies.

SUBMITTER: Bemtgen X 

PROVIDER: S-EPMC8405505 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9365977 | biostudies-literature
| S-EPMC10050067 | biostudies-literature
| S-EPMC11010074 | biostudies-literature
| S-EPMC7190048 | biostudies-literature
| S-EPMC7260457 | biostudies-literature
| S-EPMC8300481 | biostudies-literature
| S-EPMC9978549 | biostudies-literature
| S-EPMC7707150 | biostudies-literature
| S-EPMC7999389 | biostudies-literature